Actos Lawsuit Verdict: Bernstein Liebhard LLP Applauds $6.5 Million Verdict in Nation’s First Actos Bladder Cancer Trial

Share Article

The Firm is currently filing Actos bladder cancer lawsuits on behalf of long-term users of the type 2 diabetes drug.

Bernstein Liebhard LLP | Consumer Injury Lawyers
We are extremely pleased that the jury found in favor of plaintiffs. Our Firm has been closely monitoring this trial, as it could provide valuable insights into how juries might rule in similar Actos bladder cancer lawsuits.

The Los Angeles Superior Court jury hearing the nation’s first Actos lawsuit involving bladder cancer allegations has found in favor of the Plaintiff, awarding him and his wife $6.5 million in compensatory damages. According to a report from Bloomberg News, the jury deliberated for five days before finding that Takeda Pharmaceuticals failed to warn consumers that Actos could cause bladder cancer.* (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)

“We are extremely pleased that the jury found in favor of Plaintiffs. Our Firm has been closely monitoring this trial, as it could provide valuable insights into how juries might rule in similar Actos bladder cancer lawsuits,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos lawsuit evaluations to long-term users of the medication who have been diagnosed with bladder cancer.

Actos Bladder Cancer Lawsuits
Actos is one of the best-selling type 2 diabetes drugs in the world, and accounted for 27 percent of Takeda’s sales in 2011, according to Bloomberg. In June 2011, the U.S. Food & Drug Administration (FDA) ordered Takeda to add new warnings to the Actos label, after a study found that long-term use increased the risk for bladder cancer. ** The Plaintiff in the Los Angeles Actos lawsuit had taken the drug for four years before being diagnosed with the disease. During the trial, his attorneys told the jury that Takeda had known about the connection between Actos and bladder cancer since 2004, but did not inform regulators for 7 years. Evidence introduced at trial included internal Takeda emails that suggested company officials were worried about the impact an Actos bladder cancer warning would have on sales of the drug, Bloomberg reported.

Court filings indicate that Takeda has been named in more than 3,000 Actos bladder cancer lawsuits, including more than 1,200 pending in a multidistrict litigation underway in U.S. District Court, Western District of Louisiana. The first trial in that litigation is expected to begin next January. (In re: Actos Product Liability Litigation, MDL No. 2299)

Actos users who developed bladder cancer may be entitled to file an Actos lawsuit to obtain compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please contact an Actos lawyer at Bernstein Liebhard LLP today by calling (877) 779-1414.


About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website